Pharmacological inhibition of AKT1 not only diminishes RUNX2 expression but also impairs the maintenance of cancer stem-like cell populations, indicating therapeutic sensitivity of this regulatory mechanism [63,76]. Here, RUNX2 is linked to cancer.